Gismo Therapeutics Inc. is a biotech start-up focused on addressing the underlying biochemical processes associated with Alzheimer’s and Parkinson’s diseases. The company has developed a proprietary technology known as GISMO, which is based on a novel hypothesis regarding the etiology of neurodegenerative amyloid diseases. Gismo Therapeutics is dedicated to creating first-in-class, disease-modifying oral therapeutics aimed at treating both Alzheimer’s and Parkinson’s diseases. The company has received multiple prestigious research grants, including funding from the National Institutes of Health and the Michael J. Fox Foundation, to support its innovative research and development efforts.

Central to Gismo Therapeutics' approach is the exploration of small molecule compounds that target glycosaminoglycans, specifically heparan sulfate glycosaminoglycan (HS-GAG). These compounds are believed to play a critical role in the internalization and aggregation of alpha-synuclein proteopathic seeds, which are implicated in the progression of Parkinson’s disease. By investigating this newly identified disease pathway, Gismo Therapeutics aims to develop targeted therapeutics that could significantly alter the course of neurodegenerative diseases. The company’s ongoing research and development efforts are bolstered by collaborations with esteemed institutions and experts in the field, further enhancing its potential to deliver impactful treatments.

United States

GISMO THERAPEUTICS INC. is a privately funded biotech start-up company incorporated in 2011. The company is developing novel oral therapeutics for Alzheimer’s and Parkinson's Disease, based on a novel hypothesis and a novel mechanism of action. Gismo Therapeutics Inc. has ongoing research collaborations with US academic institutions.

Gismo Therapeutics

Company Details